K170558 is an FDA 510(k) clearance for the revogene. Classified as Real Time Nucleic Acid Amplification System (product code OOI), Class II - Special Controls.
Submitted by Genepoc, Inc. (Quebec, CA). The FDA issued a Cleared decision on May 25, 2017 after a review of 90 days - within the typical 510(k) review window.
This device falls under the Microbiology FDA review panel, regulated under 21 CFR 862.2570 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.